Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.

Journal of translational medicine - 13 May 2015

Ding Xiao, Cao He, Chen Xiao, Jin Haofan, Liu Ziling, Wang Guanjun, Cai Lu, Li Dan, Niu Chao, Tian Huimin, Yang Lei, Zhao Yuguang, Li Wei, Cui Jiuwei

Abstract excerpt

BACKGROUND: Small cell lung cancer (SCLC) relapses rapidly after the initial response to chemotherapy and shows drug-resistance. This study was to investigate the efficacy and safety of cellular immunotherapy (CIT) with autologous natural killer (NK), γδT, and cytokine-induced killer (CIK) cells as maintenance therapy for SCLC patients. METHODS: A pilot prospective cohort study was conducted with SCLC patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokines
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Immunotherapy

Share to Killer Cells, Natural

Share to Neoplasm Recurrence, Local

Share to Pilot Projects

Share to Small Cell Lung Carcinoma

Source

Open in PubMed Open full text

Identifiers

PMID: 25968637
DOI: 10.1186/s12967-015-0514-0
PMCID: PMC4446113

Genes

CIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.PMID 25968637Read ↗

Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a StudySemantic proximity Read ↗

DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerSemantic proximity Read ↗

Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review)Semantic proximity Read ↗

Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) TherapySemantic proximity Read ↗

Association of Lymphocyte Subsets in Advanced Non-Small Cell Lung Cancer Patients with the Efficacy and Prognosis of Immune Checkpoint Inhibitor Therapy: A Retrospective StudySemantic proximity Read ↗

Association between Natural Killer Cell Cytotoxicity and the Progression of Non-Small Cell Lung CancerSemantic proximity Read ↗

The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancerSemantic proximity Read ↗

Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3<sup>+</sup> cells in tumour infiltrateSemantic proximity Read ↗

LAG-3 and PD-1/PD-L1 inhibitors might become a promising treatment for small cell lung cancerSemantic proximity Read ↗

Towards the Development of Next-Generation Lung Cancer ImmunotherapySemantic proximity Read ↗

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerSemantic proximity Read ↗

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.